Lates News

date
20/09/2025
Nancy Ibach, Vice President of the Oncology Department of Merck USA, stated that their cancer therapy Keytruda, in its new subcutaneous injection form called Keytruda Qlex, can be administered in just one to two minutes, depending on the dosage, while intravenous infusion typically takes about 30 minutes.